Presenters
Endocrinologist, Sunway Medical Centre
Prof. Alexander Tan, MD
Course Details
Dipeptidyl peptidase 4 inhibitors (DPP4i) remain an important tool in the management of hyperglycemia in patients with type 2 diabetes. In this video, Professor Alexander Tan (Australia) shares his knowledge and experience with various DPP4is and the role of linagliptin in simplifying the complex management of diabetes.
Estimated time of Completion: 34 mins and 45 secs.
CPD Points: 1
Program Number: PROG-2024-96112
Unlock the Power of Simplicity in T2D Management Course Outline
- CARMELINA patients had higher prevalence of chronic kidney disease
compared to contemporaneuos CVOTs - CARMELINA confirmed the long-term cardiovascular safety of Linagliptin
- CARMELINA confirmed the long-term renal safety profile of Linagliptin
- CARMELINA Linagliptin was associated with significant reduction in
albuminuria progression - Cost-Effectiveness Analysis of Linagliptin in Japan Based on Results from
the Asian Subpopulation in the CARMELINA® Trial - Linagliptin on top of Standard of Care (SOC) resulted in fewer CV &
Renal events which led to better cost-effectiveness compared to SOC alone - CAROLINA evaluated the CV safety of Linagliptin vs an active comparator (glimepiride) in patients with relatively early T2D at increased CV risk
- CAROLINA Linagliptin was non-inferior to Glimepiride for 3P-MACE
- CAROLINA Linagliptin more likely to achieve HbA1c ≤7.0% without need
for rescue medication, weight gain and hypoglycaemia - VIVIDD: Vildagliptin in Ventricular Dysfunction Trial
- GUARD Efficacy, safety and albuminuria-reducing effect of Gemigliptin
in Korean T2D patients with moderate to severe renal impairment - OPTIMUS: Time to occurrence of the primary composite MACE with
Gemigliptin by treatment cohort - Linagliptin is the only DPP4i to demonstrate long-term CV and renal safety in a broad range of patients
- Unlock the Power of Simplicity: Linagliptin simplified T2D management
- Patients can trust the Quality and Safety of Boehringer Ingelheim’s Linagliptin (Trajenta®)
- Diabetes imposes an increasing economic burden on national health care
systems worldwide - Approximately one-third (32.6%) of all deaths from diabetes occur in people of working age (under the age of 60)
- Diabetes is a leading cause of CARDIOVASCULAR & RENAL disease
- Consider T2D drug that has PROVEN CARDIOVASCULAR & RENAL safety
- Approach to individualization of Glycemic Targets
- Kidney Function
- DPP-4 inhibitors: Mechanism of Action
- Not all DPP-4 inhibitors are created the same
- Linagliptin has advantageous PK-PD
- Linagliptin: Proven Efficacy for T2D patients, at par with other DPP4 inhibitors1-3
- The long-term effectiveness of Linagliptin monotherapy in a real-world setting is consistent with the efficacy profile seen in clinical trials
- Linagliptin monotherapy shows sustained HbA1c improvements regardless of kidney function in a real-world setting
- Unlike other DPP4i, Linagliptin has proven consistent efficacy across a broad range of patients as seen in RCTs and RWEs
- Linagliptin does not require dose adjustment in any level of eGFR
- 1/3 patients with T2D and CKD received inappropriate dose of DPP-4i
- Increased risk of severe hypoglycemia in the inappropriate dosing group
- Mortality was significantly higher in the inappropriate dosing group
- With Linagliptin you are always giving the appropriate dose
- Adverse CV events led US FDA and EMA to require the demonstration of CV safety for new glucose-lowering drugs
- CV outcomes trials for newer anti-diabetics (2013-2020)
- Not all inhibitors have CVOTs... and some that have a CVOT wish they didn’t have a CVOT
- Linagliptin is the only DPP-4 inhibitor supported by two unique CVOT programs: CAROLINA® and CARMELINA®, providing safety date in patients with T2D
PC-PH- 106248 | January 2025